GLP-1 use tied to weaker impulsivity-violence link

Clinical takeaway: Nothing here supports prescribing GLP-1 drugs for behavioral risk, but the signal is worth watching as use of these medications expands.

Impulsivity is one of the most durable predictors of violent behavior, but it doesn't always translate into harm at the same rate. Therapies like CBT are thought to work by weakening that translation rather than removing the trait. With GLP-1 drugs now reaching a fast-growing share of US adults, researchers asked whether they might act similarly.

Prior work gives the hypothesis some footing: GLP-1 drugs have been associated with reduced craving, lower substance use, and improved regulatory control, largely via reward and stress pathways. Whether those effects might reach violent behavior remained unknown.

Among current GLP-1 users, the link between impulsivity and violent behavior was about 62% weaker than among former users. In former users, each standard-deviation rise in impulsivity was tied to a roughly 2.8-fold increase in violent acts; among current users, that association flattened to near nothing and lost significance.

Mediation testing found no significant path from use to reduced impulsivity, pointing to a moderation effect: the drugs seemed to blunt how strongly impulsivity drove violent behavior rather than impacting the trait itself. The interaction held across weighting schemes, count models, and all three comparison groups, including current-versus-never users.

A parallel signal for alcohol use was weaker and less stable. It was underpowered and held in only one of three comparison groups.

The analysis drew on a 2025 nationally representative survey of US adults, restricted to 821 lifetime GLP-1 users and comparing 597 current users with 224 former users. Violent behavior came from a validated self-reported offending scale covering the prior 12 months. Overlap weighting balanced the two groups on impulsivity, alcohol use, weight, diabetes, and other covariates.

What this data shifts is how to think about these drugs, not how to use them. If GLP-1 drugs do blunt the link between impulsivity and aggression, that places them alongside ADHD medications and other psychiatric drugs already studied as agents that may weaken risk translation rather than erase the underlying trait. Confirming it will take longitudinal and experimental data in higher-risk populations.

"Our findings are consistent with these medications working like cognitive behavioral therapy, weakening the path from impulse to action rather than eliminating impulsivity itself," said Christopher Thomas, an assistant professor at Rutgers University-Camden and coauthor of the study.

Source: Semenza DC and Thomas C. Criminology. 2026 May 18. Glucagon-like peptide-1 receptor agonist use and violent crime among US adults